Version 5* of the COVID-19 PMB definition guideline has been released by the Council for Medical Schemes (CMS), a notable inclusion being a DTP code for COVID-19.
Other changes include PMB recommendations on serological testing and pharmacological management now being a separate section
“The WHO has published ICD-10 codes to be used for the COVID-19 and CMS recommends that correct coding be used to enable correct identification and reporting thereof,” the council has reiterated in its revised guideline introductions, adding that the new DTP has been assigned to ICD-10 codes to ensure the correct PMB classification of COVID-19.
“The surveillance for COVID-19,” it continues, “is essential to permit early recognition of suspected cases, early diagnosis, containment and prevention of onward transmission. It is also important to note that COVID-19 is a Category 1 Notifiable Medical Condition that requires immediate reporting by the most rapid means available upon diagnosis followed by a written or electronic notification to the Department of Health within 24 hours of diagnosis by health care providers, private or public health laboratories.
“Medical schemes are also required to notify and submit COVID-19 related information to the CMS, consistent with Circular 29 of 2020,” it adds.
*Version 5 can be accessed at https://www.medicalschemes.com/files/PMB%20Benefit%20definition%20guidelines/PMB_definition_guideline-COVID-19_v5.pdf